Compare AbCellera Biologics Inc (ABCL) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Procter & Gamble Co — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Procter & Gamble Co trades at $148.65 (market cap $355.69B). The key difference: Procter & Gamble Co is far larger — about 151.4× AbCellera Biologics Inc's market cap, and Procter & Gamble Co pays a 2.79% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PG | |
|---|---|---|
Market Cap | $2.35B | $355.69B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $167.18 |
52-Week Low | $2.78 | $138.10 |
Enterprise Value | $1.99B | $381.17B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Procter & Gamble (PG) trades at $148.9, down 0.27% on the day, with a bullish technical outlook supported by moving averages and key support at $148. The company reported consistent earnings beats, with Q1 2026 EPS of $1.59 exceeding the $1.56 estimate, and maintains strong cash flow from operations of $17.82B in 2025. Recent developments include a new WNBA partnership and a $1.09 dividend payment scheduled for May 2026.
PG offers stable growth with a 19.16% net income margin and a consensus price target of $159.88, implying 7% upside. Risks include premium valuations (P/E of 22.33) amid modest revenue growth and economic sensitivity. Analyst sentiment is bullish (56% buy ratings), but investors should monitor competitive pressures and inflation impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
